Basem M William
Overview
Explore the profile of Basem M William including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
889
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le B, Soror N, Ismail H, Baker M, Shetayyah S, Chung C, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Mar;
PMID: 40087059
Background: Mycosis fungoides (MF) is the commonest subtype of cutaneous T-cell lymphoma. In the United States, prior studies reported that African Americans (AA) with MF had poor outcomes. Data characterizing...
2.
Woost P, William B, Cooper B, Ueda Oshima M, Otegbeye F, De Lima M, et al.
Cytometry B Clin Cytom
. 2024 Feb;
106(1):11-24.
PMID: 38345160
The 5-azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation-inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid leukemias (AML), and under evaluation as maintenance therapy for AML postallogeneic hematopoietic...
3.
Maakaron J, William B
Drugs Aging
. 2023 Jul;
40(8):685-689.
PMID: 37432595
In the last decade, chimeric antigen receptor-T (CAR-T) cells have revolutionized the treatment of hematological malignancies. With six different products for five diseases in various settings, CAR-T use has increased,...
4.
Hanel W, Shindiapina P, Bond D, Sawalha Y, Epperla N, Voorhees T, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900230
Background: Relapsed or refractory classical Hodgkin lymphoma (cHL) remains a difficult treatment challenge. Although checkpoint inhibitors (CPI) have provided clinical benefit for these patients, responses are generally not durable, and...
5.
Chavez J, Foss F, William B, Brammer J, Smith S, Prica A, et al.
Clin Cancer Res
. 2023 Feb;
29(10):1869-1878.
PMID: 36826995
Purpose: Proliferation of T-follicular helper (TFH) CD4+ T cells is a postulated pathogenic mechanism for T-cell non-Hodgkin lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by TFH, representing...
6.
Jacobson C, Chavez J, Sehgal A, William B, Munoz J, Salles G, et al.
Lancet Oncol
. 2021 Dec;
23(1):91-103.
PMID: 34895487
Background: Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory indolent non-Hodgkin lymphoma....
7.
Schaefer A, Huang Y, Kittai A, Maakaron J, Saygin C, Brammer J, et al.
Cancer Manag Res
. 2021 Dec;
13:8901-8906.
PMID: 34876852
Introduction: Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes....
8.
Brammer J, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, et al.
J Immunother Cancer
. 2021 Aug;
9(8).
PMID: 34429331
Background: Chimeric antigen receptor T-cell (CAR-T) infusion is associated with early toxicity. Yet, whether early toxicity development holds ramifications for long-term outcomes is unknown. Methods: From a large cohort of...
9.
10.
Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson D, et al.
Cancers (Basel)
. 2021 Feb;
13(4).
PMID: 33557088
Acute graft versus host disease (aGVHD) remains a leading cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HSCT). Tacrolimus (TAC), a calcineurin inhibitor that prevents T-cell activation,...